Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387535 | 1.00 | TSHR (0.45) | TSHRALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL6386138 | 0.87 | TSHR (0.47) | TSHRALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6386142 | 0.87 | TSHR (0.47) | TSHRALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28930016 | 0.81 | TSHR (0.45) | TSHRALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL27185413 | 0.78 | TSHR (0.47) | TSHRALDH1A1NPC1RAB9ATP53 | |
| Bromide SCHEMBL25305290 | 0.78 | SRC (0.40) | TSHRALDH1A1CYP2C19SMN1; SMN2TP53 | |
| SCHEMBL28671837 | 0.77 | TSHR (0.46) | TSHRALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL7664873 | 0.76 | TSHR (0.54) | TSHRALDH1A1TP53HSD17B10MAPT | |
| SCHEMBL6385800 | 0.76 | TSHR (0.46) | TSHRALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28835869 | 0.75 | TSHR (0.45) | TSHRALDH1A1CYP1A2CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | TSHR 1035/4885ALDH1A1 2117/4885NPC1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.